Reporting of harms by randomised controlled trials in ophthalmology
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Reporting of harms in clinical trials: why do we continue to fail?
    • Imran Mahmud, Fulbright Scholar
    • Other Contributors:
      • Zara Usmani, Tahir Mahmud

    O'Day and colleagues describe in their recent paper the inadequate reporting of harm in randomized controlled trials of intra-vitreal therapies for diabetic macular oedema(O'Day et al., 2014). At first glance, the results are alarming. An average of only six recommendations of the 2004 CONSORT guidelines extension covering harms were met. Ophthalmologists are not alone in their inadequate reporting, however. Several oth...

    Show More
    Conflict of Interest:
    None declared.